The FDA opens an inside track to let Novartis race ahead on Zykadia as Roche rivalry heats up
Novartis just leaped forward with its cancer drug Zykadia (ceritinib), gaining a priority review from the FDA as a frontline treatment for ALK-positive non-small cell lung cancer as well as breakthrough status for lung cancer patients with brain metastases. The advances are keeping the pharma giant close to their fellow Basel residents at Roche in their head-to-head rivalry with Alecensa, which analysts have blessed as the odds-on winner.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
